Dexpanthenol Mouthwash to Treat Oral Mucositis

Effects of Topical Dexpanthenol on Chemotherapy and Radiotherapy Induced Oral Mucositis

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01318889

Enrollment

Registered

2011-03-21

Start date

2010-09-30

Completion date

2011-09-30

Last updated

2011-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral Mucositis (Ulcerative) Due to Radiation

Keywords

Dexpanthenol, Radiotherapy, chemotherapy, Mucositis

Brief summary

Oral mucositis can be a significant problem for cancer patients. It is typically associated with pain and increased risk of infection and can lead to impaired nutritional status and inadequate hydration.it can be seen in the patient population receiving high-dose head and neck radiation therapy (85%-100%). Topical dexpanthenol acts like a moisturizer, improving stratum corneum hydration, reducing transepidermal water loss and maintaining skin softness and elasticity. The stimulation of epithelization, granulation and mitigation of itching were the most prominent effects of formulations containing dexpanthenol. The investigators suppose that dexpanthenol mouth wash may improve oral mucositis.

Detailed description

Patients will be given a bottle of 5% Dexpanthenol mouthwash and they are asked to rinse 10 ml of it three times a day. At the onset of mucositis and then for 4 subsequent weeks they will be examined to evaluate the condition of their oral mucosa.By the advent of mucositis stage 4 ,at any time during the 4 weeks of study,the patient would be out.if any patient shows allergic reaction to dexpanthenol,he/she would be out of study too.

Interventions

DRUGDexpanthenol

5% dexpanthenol Mouth wash , three times a day, 10 cc each time

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

1. without any systemic disease 2. estimated survival of at least 6 months 3. without any mental disorders 4. grade 1 to 3 WHO mucositis

Exclusion criteria

1. development of grade 4 WHO mucositis 2. Brachytherapy 3. allergy to the drug 4. dissatisfaction of the patient

Design outcomes

Primary

Measure	Time frame	Description
reduction of intensity of mucositis	first week (week one)	measuring of the intensity of mucositis by visual examination and asking the patient about pain and discomfort

Countries

Iran

Contacts

Primary ContactFahimeh Anbari, resident

fahimeh.anbari@gmail.com+98 9197263620

Backup ContactJamileh beigom Taheri, professor

jm_taheri2006@yhoo.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026